ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

IMNN Imunon Inc

1.31
0.00 (0.00%)
Pre Market
Last Updated: 06:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Imunon Inc IMNN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 1.31 06:00:00
Open Price Low Price High Price Close Price Previous Close
1.31
more quote information »

Recent News

Date Time Source Heading
4/18/202407:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
4/11/202407:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
3/28/202407:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
3/25/202407:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
3/21/202416:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
3/13/202407:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
3/12/202416:00GLOBEIMUNON Announces Leadership Change
2/29/202407:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
2/27/202407:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
2/22/202407:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
2/09/202415:09EDGAR2Form S-1/A - General form for registration of securities..
12/29/202315:30EDGAR2Form 8-K - Current report
12/20/202316:15EDGAR2Form S-1 - General form for registration of securities under..
12/11/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202315:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/11/202307:35EDGAR2Form 8-K - Current report
12/11/202307:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
11/14/202308:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
11/14/202307:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
11/07/202307:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
10/23/202307:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
10/19/202307:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
10/18/202307:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
10/06/202307:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
9/28/202307:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
9/26/202307:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
9/13/202307:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
9/07/202315:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
9/05/202307:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
8/24/202315:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..
8/14/202307:30GLOBEIMUNON Expands Scientific Advisory Board with the Addition..
8/10/202307:00GLOBEIMUNON Reports Second Quarter 2023 Financial Results and..
8/07/202307:30GLOBEPreclinical Data Showing Strong Immunogenicity and..
8/03/202307:30GLOBEIMUNON to Hold Second Quarter 2023 Financial Results and..
6/27/202311:00GLOBEIMUNON Unveils New Manufacturing Capabilities at..
6/26/202316:00GLOBEImunon Reports Inducement Grants under NASDQ Listing Rule..
6/12/202307:30GLOBEIMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy..
6/08/202307:30GLOBEIMUNON’s CEO Presents Business Overview to Investors and..
5/30/202307:00GLOBEIMUNON Presents PlaCCine Preclinical Data at the 2023..
5/11/202307:00GLOBEIMUNON Reports First Quarter 2023 Financial Results and..
5/04/202307:30GLOBEIMUNON to Hold First Quarter 2023 Financial Results and..

Your Recent History

Delayed Upgrade Clock